绝对端粒长度与慢阻肺生活质量、急性加重及死亡率的关系
本研究基于MACRO试验中576例中重度慢阻肺患者,采用定量PCR测定外周血白细胞绝对端粒长度(aTL),以中位数分为两组,分析其与健康状态、急性加重频率及死亡率的关系。结果显示,端粒较短者圣乔治呼吸问卷评分更差;在安慰剂组中,端粒较短者的急性加重率(率比1.50,95%CI 1.16-1.95,P=.002)和死亡风险(风险比9.45,95%CI 2.85-31.36,P=.015)显著更高,而阿奇霉素组中未观察到这些差异(交互作用P=.008和P=.017)。提示端粒缩短可能预测慢阻肺不良结局。
要点
- 端粒较短的中重度慢阻肺患者健康状态更差,圣乔治呼吸问卷评分更高。
- 安慰剂组中端粒较短者急性加重率和死亡风险显著升高。
- 阿奇霉素组中端粒长度与急性加重及死亡风险无显著关联。
核心结论
- 端粒缩短可能预测慢阻肺患者不良临床结局。
- 白细胞端粒长度或可作为识别慢阻肺不良结局高风险人群的生物标志物。
研究设计与样本
- 基于MACRO研究(阿奇霉素预防慢阻肺急性加重研究)的576例中重度慢阻肺患者。
- 采用定量聚合酶链反应测定外周血白细胞绝对端粒长度(aTL)。
- 参与者接受阿奇霉素或安慰剂治疗12个月,随访约13个月评估健康状态和急性加重,额外随访29个月评估死亡率。
- 以aTL中位数将患者分为端粒较短组和较长组,比较结局差异。
主要发现
- 端粒较短者圣乔治呼吸问卷评分更高(β=-0.09,P=.034),健康状态更差。
- 安慰剂组中,端粒较短者急性加重率显著更高(率比1.50,95%CI 1.16-1.95,P=.002)。
- 安慰剂组中,端粒较短者死亡风险显著更高(风险比9.45,95%CI 2.85-31.36,P=.015)。
- 阿奇霉素组中未观察到端粒长度与急性加重或死亡风险的显著关联(交互作用P=.008和P=.017)。
关键数值与推荐
- 以aTL中位数为截断值将患者分为端粒较短组和较长组。
- 健康状态采用圣乔治呼吸问卷评分评估。
- 急性加重率以率比(RR)表示,死亡风险以风险比(HR)表示。
临床怎么用
- 白细胞端粒长度可能有助于识别慢阻肺不良结局高风险患者。
- 端粒长度与阿奇霉素治疗效应可能存在交互作用,需进一步验证。
局限性
- 研究基于MACRO试验人群,结果外推需谨慎。
- 端粒长度与结局的关联在安慰剂组中显著,阿奇霉素组未观察到,机制未明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is an age-related disease. The role of cellular senescence in COPD has not been fully elucidated. This study examined the relationship between telomere length of peripheral blood leukocytes and clinical outcomes, including health status, rate of exacerbations, and risk of mortality in individuals with COPD. METHODS: Using quantitative polymerase chain reaction, we measured the absolute telomere length (aTL) of DNA extracted from blood samples of 576 participants with moderate-to-severe COPD treated with either azithromycin or placebo for 12 months in the Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO) study. All participants were followed for approximately 13 months, during which time health status and exacerbations were carefully ascertained, and an additional 29 months for mortality. The rates of exacerbation and mortality were determined by dividing the aTL into two groups using the median value as the cutoff. RESULTS: Participants with shorter telomere length had worse health status defined by higher St. George's Respiratory Questionnaire scores (β = -0.09, P = .034). In the placebo arm of the study, the rate of exacerbation (rate ratio, 1.50; 95% CI, 1.16-1.95; P = .002) and the risk of mortality (hazard ratio, 9.45; 95% CI, 2.85-31.36; P = .015) were significantly higher in the shorter telomere group than in the longer telomere group; these differences were not observed in the azithromycin arm (interaction P = .008 for exacerbation and interaction P = .017 for mortality) CONCLUSIONS: These data suggest that replicative senescence may help to predict poor outcomes in COPD. Shorter leukocyte telomere lengths may represent a clinically translatable biomarker for identifying individuals at increased risk of poor clinical outcomes in COPD.
引用
- Jin M, Lee EC, Ra SW, et al. Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. Chest. 2018. PMID: 30017346. doi:10.1016/j.chest.2018.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。